ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkins Lymphoma: A Single Center Experience
The Korean Journal of Internal Medicine
;
: 159-164, 2006.
Article
in English
| WPRIM
| ID: wpr-67637
ABSTRACT
BACKGROUND:
The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine whether ESHAP therapy would be effective and well-tolerated in Korean patients.METHODS:
Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study. We retrospectively evaluated the treatment response, the survival rate and the time to progression.RESULTS:
Six patients (27.3%) attained complete remission and eight patients (36.4%) attained partial remission. The overall response rate was 63.6%. The median survival duration was 15.5 months (95% confidence interval; 10.7 to 20.3 months), and the median duration of the time to progression was 8.3 months (95% confidence interval; 0.3 to 16.3 months). Myelosuppression was the major toxicity, but severe neutropenia or thrombocytopenia was rare, and renal toxicity was also infrequent.CONCLUSIONS:
ESHAP regimen is effective in Korean patients suffering with relapsed or refractory NHLs, but a more effective salvage modality is needed because of the short duration of remission and the insignificant impact on long-term survival.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Lymphoma, Non-Hodgkin
/
Methylprednisolone
/
Prednisone
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Analysis
/
Cisplatin
/
Salvage Therapy
/
Treatment Failure
/
Disease Progression
/
Cytarabine
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
The Korean Journal of Internal Medicine
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS